Enovis Corporation $ENOV Position Reduced by Dorsey Asset Management LLC

Dorsey Asset Management LLC decreased its holdings in Enovis Corporation (NYSE:ENOV) by 5.0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,279,200 shares of the company’s stock after selling 120,122 shares during the period. Enovis makes up about 5.3% of Dorsey Asset Management LLC’s investment portfolio, making the stock its 10th largest position. Dorsey Asset Management LLC’s holdings in Enovis were worth $60,718,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Enovis by 2.0% in the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after buying an additional 125,460 shares during the period. Dimensional Fund Advisors LP grew its position in Enovis by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after acquiring an additional 51,201 shares in the last quarter. Rubric Capital Management LP acquired a new stake in Enovis in the third quarter valued at approximately $83,435,000. Paradigm Capital Management Inc. NY grew its position in Enovis by 41.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock valued at $34,913,000 after acquiring an additional 326,900 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Enovis by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 951,718 shares of the company’s stock valued at $25,354,000 after acquiring an additional 24,558 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased a total of 4,200 shares of company stock worth $92,084 over the last three months. 2.90% of the stock is currently owned by company insiders.

Enovis Stock Up 2.8%

Shares of NYSE:ENOV opened at $21.56 on Wednesday. Enovis Corporation has a 52-week low of $20.55 and a 52-week high of $36.82. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -1.08 and a beta of 1.38. The company has a 50 day moving average of $23.97 and a two-hundred day moving average of $24.44.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter last year, the company earned $0.81 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts forecast that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ENOV shares. Evercore reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a research report on Friday, May 8th. Zacks Research downgraded shares of Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Wells Fargo & Company lowered their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Enovis in a research report on Friday, May 22nd. Finally, Needham & Company LLC increased their price objective on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.50.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.